Marie Curie Cancer Care and Cancer Research Technology extend their relationship through the completion of a technology transfer agreement
Cancer Research Technology (CRT), a specialist oncology focussed technology transfer and development company, has announced the completion of a technology transfer agreement with Marie Curie Cancer Care, one of the largest cancer charities in the UK.
CRT has been granted an exclusive option to assist in the development and commercialisation of any cancer related discoveries arising from the Marie Curie Research Institute (MCRI), the research institute which is part of Marie Curie Cancer Care.
Peter O'Hare, director of the MCRI, said of this agreement: "This enhances our relationship with CRT.
"With MCRI research expertise in key areas of cancer biology and the expertise of CRT in technology development and commercialisation, together we aim to maximise opportunity for research to bring benefit to cancer patients".
The deal expands an existing relationship, in part by enabling MCRI to work directly with CRT's development laboratory.
CRT is distinctive among technology transfer organisations in having its own development laboratory, with core competences in molecular and cellular biology, drug discovery, medicinal chemistry and early pharmacology.
The laboratory plays a key role within CRT in adding value to a scientist's initial invention, enhancing its potential for commercialisation and therefore cancer patient benefit.
Marie Curie Research Institute scientists work at the boundaries of existing knowledge, seeking to find out more about the cellular mechanisms responsible for the development of cancer.
Their work may identify novel anti-cancer targets, or completely new therapeutic strategies - but further development is needed to convert experimental results into therapies that can be used in the clinic.
Keith Blundy, CRT's chief operating officer, added: "The signing of this technology transfer agreement marks a significant and exciting milestone in our relationship with Marie Curie Cancer Care.
"Both organisations are united in their mission of seeking cancer patient benefit and CRT looks forward to joining forces with scientists at the MCRI to achieve this."
